Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | GRM5 | P41594 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5909363 | 0.85 | HDAC8 (0.83) | HDAC8HDAC6L3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL17236166 | 0.83 | SMN1; SMN2 (0.77) | L3MBTL1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL17336774 | 0.83 | KDM4E (0.64) | HDAC8HDAC6L3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL31305679 | 0.83 | KDM4E (0.64) | HDAC8HDAC6L3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL17336679 | 0.82 | SMN1; SMN2 (0.64) | L3MBTL1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL20198539 | 0.82 | CYP1A2 (0.57) | L3MBTL1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL5426936 | 0.81 | L3MBTL1 (0.75) | L3MBTL1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL30618513 | 0.81 | L3MBTL1 (0.75) | L3MBTL1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL20669813 | 0.81 | PARP1 (0.53) | HDAC8HDAC6L3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL6960873 | 0.80 | PARP1 (0.62) | L3MBTL1SMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| CN-120004754-A | Preparation method of high-purity N-methyl halogenated benzamide | 福州大学 | 2025-05-16 | — | — | CN | disclosed |
| CN-115991705-B | 3- (1H pyrrolo [2,3-b ] pyridin-5-yl) benzoyl derivatives, preparation and application thereof | 安徽医科大学 | 2025-04-08 | — | — | CN | disclosed |
| EP-4499149-A1 | PROTEIN DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2024175081-A1 | SHP2 INHIBITOR COMPOUND AND USE THEREOF | 深圳真实生物医药科技有限公司 | 2024-08-29 | — | — | WO | disclosed |
| CN-115872947-B | Benzisothiazole benzamide compound or pharmaceutically acceptable salt thereof, preparation method and application | 中国药科大学 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-6518257-B1 | 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| US-20030027847-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-06 | — | — | US | disclosed |
| WO-2001096283-A9 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2002-10-17 | — | — | WO | disclosed |
| EP-1227086-A1 | 1-SUBSTITUTED PHENYL-1-(1H-IMIDAZOL-4-YL) ALCOHOLS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001096283-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| US-6300352-B1 | FOR THERAPY OF ASTHMA | ASTRAZENECA AB (SE) | 2001-10-09 | — | — | US | disclosed |
| CN-1257481-A | Pyridine derivatives and pharmaceutical compositions containing them | ASTRA PHARMA PROD (GB) | 2000-06-21 | — | — | CN | disclosed |
| EP-0971892-A1 | NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Astra Pharmaceuticals Limited (GB) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998042670-A1 | NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-10-01 | — | — | WO | disclosed |
| WO-1995027692-A1 | SUBTITUTED BIPHENYL TNF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | HDAC8 4098/4885HDAC6 3273/4885L3MBTL1 1947/4885 |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | HDAC8 28/4885HDAC6 123/4885L3MBTL1 2833/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | HDAC8 2798/4885HDAC6 690/4885L3MBTL1 969/4885 |
| US-20030027847-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | HDAC8 1057/4885HDAC6 2328/4885L3MBTL1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.